Dozirani pripravak valdekoksiba za topičku primjenu: Priprava i farmakološka evaluacija by K. S. KESAVANARAYANAN et al.
Non steroidal anti inflammatory drugs (NSAIDs) have been increasingly introduc-
ed as topical preparations for local treatment of musculoskeletal soft tissue rheumatic
conditions (1). This concept may be extended to the selective COX-2 inhibitors, so as to
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Valdecoxib, a selective COX-2 inhibitor, produces seri-
ous side effects when given orally. This has led to its with-
drawal. Topical application of valdecoxib was formulat-
ed and evaluated for its efficacy and safety. Standard
procedures were followed and male Wistar albino rats
were used to test the anti-inflammatory effect and effect
in hyperalgesic conditions. Ointments, creams, and gels
containing valdecoxib 1% (m/m) were prepared. These
were tested for physical appearance, pH, spreadability,
drug content uniformity, in vitro diffusion. Gel prepared
using Carbopol 940 (F-X) was selected after the analysis
of the results. Formulation F-X was evaluated for acute
skin irritancy, anti-inflammatory effect, optimum effective
concentration of valdecoxib, effect on hyperalgesia, inhi-
bition of the granulation tissue formation and anti-ar-
thritic effect. Determination of valdecoxib in test animals
plasma and determining the blood clotting time and ble-
eding time were conducted to study the safety of topical
valdecoxib. Valdecoxib gel containing 1% (m/m) of the
drug was significantly (p < 0.05) more effective in inhib-
iting hyperalgesia associated with inflammation, compar-
ed to placebo gel, but exhibited significantly (p < 0.05)
lower suppression of inflammation than commercial rofe-
coxib gel. Concentration of valdecoxib used in the prepara-
tion minimizes the risk of systemic effects, as shown by
the analysis of rat plasma for the presence of valdecoxib;
hence, this may be the alternative to oral preparations.
The bleeding and clotting time showed no significant dif-
ference before and after application of F-X.
Keywords: valdecoxib, topical gel, in vitro, in vivo evalua-
tion
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minimize their side effects. The side effects cited for valdecoxib pose increased risk of
cardiovascular events and well-described serious potentially life threatening gastroin-
testinal bleeding (2). The selection of vehicle bases decides the consistency, physical pro-
perties and also affects the drug release from the preparations (3). Therefore in this work,
different bases were selected for pharmaceutical evaluation. Topical administration re-
quires lower doses when compared with that of oral dosage forms, hence it is hypothe-
sized that systemic absorption may be negligible. An add internal advantage of local-
ized peripheral administration is optimization of drug concentration at the site of the
origin of pain, leading to lower systemic levels with fewer adverse effects (4). In this
work, the efficacy of using valdecoxib as a topical preparation is evaluated by pharma-
ceutical tests and pharmacological evaluation and was compared with the commercial
topical rofecoxib preparation.
EXPERIMENTAL
Valdecoxib was a gift sample from Safe Line Formulation (India). Carbopol 940 was
purchased from B-Pura Labs (India). Commercial sample of rofecoxib 1% (m/m) was
purchased from a retail pharmacy shop. Heat-killed Mycobacterium tuberculosis H37RA
was procured from the Indian Council for Medical Research (ICMR) (India). Carrage-
enean was purchased from Sigma Chemicals (USA). Other chemicals used were of ana-
lytical reagent grade.
UV spectrophotometer (Shimadzu model 1601, Shimadzu, Japan), pH meter (Sys-
tronics, India), penetrometer (Systronics), Franz diffusion cell were the apparatus used.
Formulations
Fourteen different formulations were prepared using an ointment base, a cream base
and a gel base according to the formulae given in Table I.
Appropriate standard method of fusion (where the solid fats were melted and mix-
ed) and trituration were followed for preparation of the ointment, cream and gel (5).
Valdecoxib was incorporated in the bases to get 1% (m/m). All preparations were pack-
ed in wide-mouthed transparent plastic jars with screw-capped lids. The following tests
were carried out on all the preparations.
Drug content
Each formulation (500 mg) was weighed and 0.5 mol L–1 sodium hydroxide was
added and triturated. Valdecoxib was extracted in the medium and was made up to 100
mL with the same. After filtration of this stock, suitable dilutions were made, if neces-
sary, and absorbance was measured at 244 nm. Drug content was calculated from the
linear regression equation obtained from the calibration data. Results given in Table I are
the average of triplicate values.
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Table I. Formulae and drug contents of ointment, cream and gel
Formulation Ingredients
Concentration (%, m/m) Drug content
mean ± SD (%)
F-I Emulsifying wax 3 0.75 ± 0.51
Soft paraffin 50
Liquid paraffin 20
F-II Emulsifying wax 20 0.76 ± 0.52
Soft paraffin 60
Liquid paraffin 20
F-III Emulsifying wax 25 1.10 ± 1.14
Soft paraffin 55
Liquid paraffin 20













F-VII Emulsifying ointment 40 1.20 ± 0.38
Chlorocresol 1
Purified water 59
F-VIII Emulsifying ointment 30 1.58 ± 1.23
Chlorocresol 1
Purified water 69




Purified water q.s 100




Purified water q.s. 100
Drug release
In vitro diffusion study was performed using the Franz diffusion cell (6, 7). Phos-
phate buffer pH 7.4 was used as receptor fluid and dehaired abdominal skin of Wistar
albino rats was used as a semi permeable membrane. On the dorsal side of the skin,
which is exposed to the donor compartment, 100 mg of formulation was placed and
samples of 5 mL were withdrawn at intervals of 90 minutes. Fresh phosphate buffer pH
7.4 (5 mL) was replaced to maintain a volume of receptor fluid. The samples were ana-
lyzed at 244 nm against fresh receptor fluid as blank. Diffusion was carried out in the
same manner as for the test formulations for the bases used in the formulations without
incorporating valdecoxib. Diffusion profile of valdecoxib from all formulations was cal-
culated, as described above. Results are given in Fig. I.
Physical evaluation
Physical appearance was observed visually. pH was measured using a pH meter.
Spreadability was observed by spreading 1 g of formulation on a clean even glass sur-
face. Consistency was measured by measuring the yield value using a penetrometer (8,
9). Stability of the gel was determined by observing syneresis following the freeze-thaw
cycle (8, 9).
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Formulation Ingredients
Concentration (%, m/m) Drug content
mean ± SD (%)




Purified water q.s. 100




Purified water q.s. 100




Purified water q.s. 100




Purified water q.s. 100
Table I. continued
Pharmacological evaluation
Male Wistar albino rats, 4–6 weeks old, weighing 120–180 g, were used for the stud-
ies. Each group consisted of six animals. The animals were fed a balanced rodent pellet
diet and tap water ad libitum. All animals were obtained from inbred strains from the C.
L. Baid Metha College of Pharmacy’s animal house (Chennai, India). The study protocol
was approved by the institutional animal ethics committee. The animals were housed at
room temperature of 28 ± 1 °C with 12 h light/dark cycle. All animals were randomly
assigned to different groups and a period of one month was allowed for adaptation be-
fore commencement of each experiment. In all evaluations group I (control) was the pla-
cebo group (F-O); group II was reference standard (rofecoxib gel, 1%, m/m) group and
groups III, IV, V and VI were test groups (F-X, F-Xa, F-Xb, F-Xc) with 1, 0.5, 1.5 and 2%
(m/m) valdecoxil in the gel, respectively (see Table I).
Acute skin irritation study
Dorsal hairs at the back of the rats were clipped off one day prior to the commence-
ment of the study. Animals showing normal skin texture were housed individually in
cages with copography meshes to avoid contact with the bedding. One side of each ani-
mal was used for intact study and the other for testing on abraded skin. Abrasion was
non-bleeding incision of stratum corneum. About 50 mg of test sample was applied over
one square centimeter area of intact and abraded skin. Animals were immobilized in a
restrainer for 24 h. Skin responses were evaluated according to the visual analog scale
used in the Draize technique (10, 11).
Inhibition of carrageenean induced paw edema (acute model)
Test samples containing 0.5% (group IV), 1% (group III), 1.5% (group V), 2% (group
VI) (m/m) of valdecoxib in the gel base were prepared and examined for topical anti-in-
flammatory action as described above. Results are given in Table II.
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Fig. 1. In vitro diffusion profile of F-I to F-X (mean ± SD, n = 3).
Volume of unilateral hind paws of test animals was measured. On each paw, 100 mg
of test preparation was carefully rubbed twice 1 and 2 h before carrageenean administra-
tion. The test animals were placed in cages with meshes to avoid coprophagy. 0.1 mL of
carregeenean 1% (m/V) was injected subcutaneously into the paw and the volume of
hind paw was measured at hourly intervals for 5 h using a mercury plethysmometer (10,
11). Percentage inhibition was calculated. Results are given in Table II.
Inhibition of carrageenean induced hyperalgesia
An exaggerated response to moderate stimuli in a paw injected with carrageenean
was evaluated by the standard method (12), where the thermally evoked paw withdraw-
al latency was determined. Results are given in Table III.
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Table II. Inhibition of carrageenean induced paw edemaa
Group
Edema volume (mean ± SEM, mL)b,c after
1 h 2 h 3 h 4 h 5 h
I 0.15 ± 0.04 0.19 ± 0.04 0.26 ± 0.06 0.30 ± 0.06 0.34 ± 0.06


















































a Dose per paw applied – 200 mg valdecoxib except for the control in which placebo gel was used.
b Each group has 6 animals.
c Inhibition (%) is given in parentheses.
d Significant difference compared to group I (control) (p < 0.05).
Table III. Inhibition of hyperalgesia
Group
Paw withdrawal latency (mean ± SEM, s) after
1 h 2 h 3 h 4 h
I 4.3 ± 0.4 3.1 ± 0.4 2.7 ± 0.3 2.7 ± 0.3
II 11.2 ± 0.3a 9.3 ± 0.2a,b 9.2 ± 0.4a,b 8.2 ± 0.3a,b
III 11.6 ± 0.3a 11.2 ± 0.3a,b 10.3 ± 0.3a,b 9.5 ± 0.2a,b
a Significant difference compared to group I (control) (p < 0.05).
b Significant difference between groups II and III (p < 0.05).
Inhibition of proliferation of the granulation tissue (sub-acute model)
Sterile cotton (20 ± 1 mg) soaked in 0.2 mL of distilled water containing penicillin (0.1
mg) and streptomycin (0.13 mg) was implanted subcutaneously bilaterally in the lumbar
region under ether anesthesia and animals were divided into three groups (control, stan-
dard, test). Topical application (twice a day for seven days) of the preparation was done
on normal skin over the cotton-implanted site. On the 8th day after sacrifice, granular tis-
sue, proliferated around the cotton was removed, dried (60 °C for 24 h) and weighed.
Mass of the tissue was determined and used as the basis for evaluation (13, 14).
Inhibition of adjuvant arthritis (chronic model)
Heat-killed Mycobacterium tuberculosis H37RA was used to prepare complete Freund’s
adjuvant (15). The prepared complete Freund’s adjuvant (0.1 mL equivalent to 0.6 mg),
was injected subcutaneously into the plantar site of the right hind paw of male Wistar
albino rats under ether anaesthesia. After 14 day, animals with secondary inflammation
(left hind foot, bilateral front foot and/or tail) were selected. On the 15th day, the test
and standard preparations were applied once a day for 7 days. After 5 h, the paw was
rinsed with warm water and edema was measured daily on the right hind paw for 7
days. Results are given in Table IV.
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Table IV. Inhibition of adjuvant arthritis
Day
Group I Group II Group III
Paw volume (mean ± SEM, n = 6, mL)a,b
1 0.11 ± 0.0 0.12 ± 0.0 0.11 ± 0.01




























a Values in parentheses indicate the percentage of reduction in paw volume compared to the control.
b Significant difference compared group I (control) (p < 0.05).
Valdecoxib concentration in plasma and bleeding and clotting time
Gel formulation F-X (100 mg) was applied on the hind paw of six healthy male Wistar
rats, twice a day for one week, blood was collected by retro-orbital puncture. Plasma
samples were analyzed for valdecoxib by the reported RP-HPLC method (16).
Blood clotting time and bleeding time of the rats were measured by the reported
method (17). Following this, F-X (100 mg) was applied on the hind paw of the test ani-
mals twice a day for one week. Blood clotting and bleeding time were measured after
this treatment.
Statistical analysis
All results are expressed as mean ± SD or mean ± SEM. Differences were compared
using one-way ANOVA followed by Dunnet’s t-test.
RESULTS AND DISCUSSION
Valdecoxib content in all prepared formulations F-I to F-X was theoretically 1% (m/m).
In evaluation, it varied between 0.75 ± 0.51 and 1.58 ± 1.23 (mean ± SD, %). Among the
preparations, F-IX and F-X, which are gels prepared using Carbopol and Carbopol 940,
respectively, exhibited drug contents of 1.04 ± 0.16 and 0.98 ± 0.25 (mean ± SD, %).
Drug release results show that F-IX and F-X release more than 40% of the drug within
the first 15 minutes and F-X releases a maximum of 95.6% after 90 minutes (Fig. 1). Other
preparations did not release valdecoxib to the extent observed for F-IX and F-X. Based
on the above results, F-X was selected for further study.
Physical appearance was observed visually. F-X was translucent, smooth in texture.
pH was 6.7 ± 0.1. This is approximately neutral and may be suited for topical applica-
tion without any discomfort. F-X gel spreads smoothly on a clean even glass plate with
minimum pressure without any solid or gritty particles. Yield value measured for F-X
was (121.6 ± 0.1) ´ 10–5 kPa. There was no syneresis for F-X when subjected to the freeze-
-thaw cycle formulations. Absence of syneresis is an indicator of gel stability. The results
show that the gel base with Carbopol 940 (F-X) is pharmaceutically acceptable for for-
mulating valdecoxib.
Preliminary test for irritation resulted in selecting the gel for further tests because it
proved to be non-irritant. As valdecoxib is 28,000 times more selective in binding with
COX-2 receptor than with COX-1 and rofecoxib is 800 times more selective (18), hence,
effectiveness of valdecoxib was evaluated against rofecoxib. Also, in clinical trials rofe-
coxib was used for comparison with valdecoxib (19).
In the pharmacological test, valdecoxib gel showed a significant anti-inflammatory
activity when tested on various models of inflammation. Commercial gel containing ro-
fecoxib was used as reference standard in all evaluations. In the acute model, test formu-
lation F-X showed 61.8% inhibition. The reference standard, rofecoxib gel showed 70.6%
inhibition (Table II). In the subacute model of inflammation, reference rofecoxib showed
significantly (p < 0.05) better anti-proliferative effect (61.8%), than formulated valdeco-
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xib in F-X (41.2%). Valdecoxib at 0.5% (m/m) was ineffective in reducing edema and at
1.5 and 2.0% no significant added effect was seen compared to 1% valdecoxib added. In
the chronic model (Table IV), rofecoxib exhibited significant (p < 0.05) inhibition to the
extent of 64.3% on the 19th day after adjuvant induction and formulated valdecoxib show-
ed 60.7% 21 days after adjuvant induction. In this study, rofecoxib was significantly (p <
0.05) better than both placebo gel and F-X. Valdecoxib gel F-X possessed significant anti-
-nociceptive effect topically, as observed in the carrageenean induced hyperalgesia model
(Table III). The paw withdrawal latency was evaluated at hourly intervals for a period of
4 h from the time of the application of the placebo gel, reference standard and F-X. The
paw withdrawal latency was enhanced to 9.5 seconds with F-X valdecoxib gel, 8 seconds
with commercial rofecoxib gel against the 2.6 seconds for the control at the end of the 4th
hour. There is a significant (p < 0.05) difference between the control and group III that re-
ceived treatment with F-X formulation. Group III also exhibits significant (p < 0.05) dif-
ference in pain perception as exhibited by prolongation in the paw withdrawal latency
after the 2nd, 3rd and 4th hours when compared to group II. This shows that the anti-no-
ceptive effect is better for valdecoxib (F-X) than rofecoxib (commercial gel-reference stan-
dard). This observation is in concurrence with the results of a study done by Christensen
et al. (20), who reported that valdecoxib was superior to rofecoxib in relieving acute post-
-surgical pain when administered orally. The optimum drug concentration required to
elicit anti-inflammatory effect was found to be 1% m/m To conclude, rofecoxib gel is sig-
nificantly better for anti-inflammatory action whereas valdecoxib gel is more effective
for the anti-nociceptive action in the carrageenean induced hyperalgesia model.
Serious side effects of valdecoxib may be due to the expression of COX-2 receptors
in vascular endothelium (16). Literature reports show that daily administration of 10 mg
kg–1 body mass of valdecoxib to male Wistar rats, along with aspirin at a dose of 100 mg
kg–1 body mass, continuously for 4 weeks significantly alters certain hemostatic parame-
ters. The blood plasma level of valdecoxib above 101.1 ng mL–1 is associated with risks
like alteration in cardiovascular events (16). A preliminary attempt to quantitatively esti-
mate valdecoxib in rat plasma was executed by the RP-HPLC method. Valdecoxib was
not detected by the reported method. This tentatively proves that valdecoxib is not ab-
sorbed to a measurable extent in the systemic circulation after local application. There-
fore, it may be hypothesized that F-X gel is safe without any serious side effects. Blood
clotting time and bleeding time were 124 ± 4 (mean ± SEM, n = 6) (in seconds), 87 ± 2 be-
fore treatment, and 123 ± 3 and 88 ± 3, respectively, after treatment. There is no signifi-
cant difference in blood bleeding and clotting time before and after treatment.
CONCLUSIONS
Topical route of application has a great potential as an effective and safe way to ad-
minister valdecoxib for local analgesic effect. Preliminary blood tests in rats may indi-
cate negligible systemic absorption and side-effects. Not detectable levels of valdecoxib
in the animals plasma may point to negligible systemic absorption, thereby leading to
negligible side-effects. Blood bleeding and clotting times were not affected. Further ex-
periments are to be conducted in other animal models for analgesic and anti-inflamma-
tory effect. Based on the results of these tests, trials may be performed on humans.
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S A @ E T A K
Dozirani pripravak valdekoksiba za topi~ku primjenu:
Priprava i farmakolo{ka evaluacija
K. S. KESAVANARAYANAN, MOHANAVELU NAPPINNAI i RAJU ILAVARASAN
Valdekoksib, selektivni COX-2 inhibitor, primijenjen peroralno urokuje ozbiljne nus-
pojave, zbog ~ega je povu~en iz uporabe. U ovom radu izra|en je i evaluiran pripravak
valdekoksiba za topi~ku primjenu. Uporabljeni su standardni postupci za procjenjivanje
protuupalnog i analgetskog djelovanja na mu{kim Wistar albino {takorima. Prire|ene su
masti, kreme i gelovi s udjelom valdekoksiba od 1% (m/m) kojima je procijenjen fizi~ki
izgled, pH, mazivost, ujedna~enost sadr`aja ljekovite tvari, in vitro difuzija. Nakon analize
rezultata, za farmakolo{ka ispitivanja je izabran gel s Carbopol 940 (F-X). Procijenjena je
akutna iritacija ko`e tog pripravka, njegov protuupalni u~inak, optimalna koncentracija
valdekoksiba, u~inak na stanje hiperalgezije, inhibicija stvaranja granulocita i antiartri-
ti~ni u~inak. Za procjenu sigurnosti topi~ke primjene valdekoksiba, odre|ena je njegova
koncentracija u krvnoj plazmi, te vrijeme zgru{avanja krvi. Gel s udjelom valdekoksiba
1% (m/m) imao je zna~ajno ve}i u~inak u inhibiciji hiperalgezije povezane s upalom (p <
0,05) nego placebo pripravak, ali je imao zna~ajno manji u~inak (p < 0,05) od gela s ro-
fekoksibom. Analiza plazme na prisutnost valdekoksiba ukazuje na niski rizik sistem-
skog u~inka. Vrijeme krvarenja i zgru{avanja nije se bitno promijenilo prije i poslije upo-
rabe F-X. Zbog toga bi ovaj pripravak mogao biti alternativa peroralnim pripravcima.
Klju~ne rije~i: valdekoksib, gel za topi~ku primjenu, in vitro, in vivo evaluacija
Department of Pharmacology, C. L. Baid Metha College of Pharmacy, Thoraipakkam, Chennai-600096
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